Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study points to DNA test for myelodysplasia blood disorder:

This article was originally published in Clinica

Executive Summary

A US team is working on a promising DNA test for the early diagnosis of a serious blood disorder that can lead to bone marrow failure and acute myelogenous leukemia. Myelodysplastic syndrome, diagnosed in about 15,000 to 20,000 people a year, is often difficult to distinguish from readily treatable, nonmalignant forms of bone marrow disease. Therapeutic options for the condition are expected to be improved with early diagnosis. The new test, described in the Proceedings of the National Academy of Sciences (April 6), is being developed by researchers from the Pacific Northwest Research Institute in Seattle. It is performed on white cells extracted from a small volume of the patient's blood. The DNA is analysed by a technique called Fourier transform-infrared (FT-IR) spectroscopy in conjunction with statistical models.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT057801

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel